Wednesday, 20 February

08:00 – 09:30 Davos 2

Session 1: Aortic Valve Disease

Chairs:
T. F. Lüscher, London, Zurich
F. Maisano, Zurich

08:00 – 08:20

Imaging to select patients with bicuspid valve for TAVI

J. J. Bax, Leiden
08:20 – 08:40

Long-term results of TAVI: Will it overcome surgery?

S. Windecker, Berne
08:40 – 09:00

Expanding indications for TAVI

R. Binder, Wels
09:00 – 09:20

Optimal antithrombotic therapy in patients with valvular heart disease

M. Valgimigli, Berne
09:20 – 09:30

Panel discussion

09:30 – 10:00

Coffee


10:00 – 11:30 Davos 2

Session 2: Heart Failure

Chairs:
B. Pitt, Ann Arbor
F. Ruschitzka, Zurich

10:00 – 10:20

Risk stratification in chronic HF

M. F. Piepoli, Piacenza
10:20 – 10:40

Use of biomarkers to guide treatment of HF ─ the time is now

A. S. Maisel, San Diego/Basel
10:40 – 11:00

HFpEF: a misunderstood disease in search of a therapy

S. D. Solomon, Boston
11:00 – 11:20

Geographic variations of heart failure: Does it matter?

S. Yusuf, Hamilton
11:20 – 11:30

Panel discussion

11:30 – 11:45 Davos 2

Poster Award

Chairs:
G. G. Camici, Zurich
P. Libby, Boston

12:00 – 13:15 Davos 2

Satellite Symposium Vifor Pharma (a lunch bag will be offered)

Comorbidities in Heart Failure: The devil is in the details

Chairman:
P. Ponikowski, Wrozlaw

12:00 – 12:25

Iron deficiency, a negative prognostic factor in heart failure

O. Pfister, Basel
12:25 – 12:50

Hyperkalemia management or how to optimize treatment with RAAS inhibitors

P. Ponikowski, Wrozlaw
12:50 – 13:15

Panel discussion

13:30 – 14:30 Schwarzhorn

Meet the Expert Session ─ Heart Failure

Panel and Case Presenters:
D. Milicic, Zagreb
S. D. Solomon, Boston
M. T. Mäder, St. Gallen
O. Pfister, Basel

13:30 – 14:30 Seehorn

Meet the Expert Session ─ Myocarditis

Panel and speakers:
U. Eriksson, Wetzikon
B. Heidecker, Berlin

14:30 – 14:45

Coffee


14:45 – 15:45 Davos 2

Session 3: Comorbidities in Heart Failure

Chairs:
D. Milicic, Zagreb
K. B. Swedberg, Gothenburg

14:45 – 15:05

HF and anaemia ─ when and how to treat?

P. Ponikowski, Wrozlaw
15:05 – 15:25

Antithrombotic therapy and HF

J. Cleland, Glasgow
15:25 – 15:45

Chronic obstructive lung disease in HF

S. Ulrich Somaini, Zurich
15:45 – 16:00 Davos 2

Wrap Up and Closing Remarks

Chairs:
B. Pitt, Ann Arbor
T. F. Lüscher, London, Zurich